BridgeBio Pharma vs TG Therapeutics
BBIO and TGTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BBIO and TGTX compare
BridgeBio Pharma is the larger company, worth 1.6 times as much as TG Therapeutics ($14.7B against $9.4B).
BridgeBio Pharma grew revenue faster over the last twelve months (167% versus 76.1% for TG Therapeutics).
TG Therapeutics scores higher on the StockData Score (10 against 3 for BridgeBio Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BBIO | TGTX |
|---|---|---|
| Size and price | ||
| Market cap | $14.7B | $9.4B |
| Share price | $74.95 | $61.18 |
| Change, 1 year | 12.5% | 81.1% |
| Change, 5 years | 40.3% | 72.3% |
| Beta (5Y) | 1.13 | 1.73 |
| Employees | 834 | 399 |
| StockData Score | ||
| Total score | 3 | 10 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 2 | 2 |
| Performance score | 0 | 4 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 22.3× |
| P/S | 15.5× | 11.7× (better) |
| P/B | – | 15.5× |
| EV/EBITDA | – | 69.6× |
| P/FCF | – | 539× |
| FCF yield | −2.5% | 0.19% (better) |
| Fair value | – | $76.21 |
| Margin of safety | – | 19.7% |
| Growth | ||
| Revenue growth (TTM) | 167% (better) | 76.1% |
| Revenue growth, 5Y average | 127% | 427% (better) |
| Net income growth (TTM) | – | 630% |
| EPS growth (TTM) | – | 641% |
| Profitability | ||
| Gross margin | 94.3% (better) | 82.4% |
| Operating margin | −38.5% | 17.1% (better) |
| Net margin | – | 55.2% |
| FCF margin | −39.1% | 2.2% (better) |
| Return on equity | – | 100% |
| Return on invested capital | – | 27.8% |
| Financial health | ||
| Debt / equity | – | 1.23 |
| Net debt / EBITDA | – | 0.98 |
| Interest coverage | −7.1× | 3.6× (better) |
| Current ratio | 2.09 | 4.27 (better) |
| Altman Z-score | 0.06 | 5.93 (better) |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Buyback yield | 1.7% | 1.9% (better) |
| Shareholder yield | 1.7% | 1.9% (better) |
| Ownership | ||
| Held by institutions | 99.1% | 72.6% |
| Held by insiders | 35.5% | 16.1% |
| Insider net buying, 12 months | −$105M | −$438K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 15.6% | 23.8% |
Go deeper
- BBIO stock overview
- BBIO income statement
- BBIO valuation and score
- TGTX stock overview
- TGTX income statement
- TGTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.